Conformis (Nasdaq:CFMS) today announced the first procedure performed with its new Actera hip system for hip reconstruction.
Billerica, Massachusetts–based Conformis designed its Actera hip system with a cutting-edge, tri-taper stem. It features a range of sizes and angles derived from Conformis’ deep data analytics of its patient database. The cementless hip stem component also includes a proximally coated titanium spray with a hydroxyapatite layer. This encourages initial and long-term fixation.
Dr. William Kurtz performed the hip replacement procedure at Ascension Saint Thomas Hospital in Nashville, Tennessee. He used a minimally invasive, direct-anterior approach.
“The Actera hip system is a great new option for hip reconstruction surgeons,” said Dr. Kurtz. “Conformis’ addition of a tri-taper stem design enables surgeons to treat a broader range of patient anatomies, and the shorter length options offer easier access to the femur while maintaining the fixation and integrity required for long-term success of the implant.”
Conformis has an ongoing U.S. rollout at select sites. It anticipates a full commercial launch for Actera in mid-2023. Conformis expects the platform to feature several personalization options, even for complex anatomies.
“We are pleased with the initial interest and positive reception of our Actera Hip System, which is part of Conformis’ continued efforts to be at the forefront of design, technology and personalization in total joint replacement,” said Mark Augusti, president and CEO of Conformis. “This exciting new addition to our portfolio allows us to expand our offering to surgeons treating patients in need of hip replacement surgery.”
More on Actera
Conformis offers Actera in variable collar lengths. This helps to avoid the overhang or stem subsidence that can occur when using implants with fixed collar lengths. Additionally, the system features two head-center options in each size.
The company labeled Actera a “major building block for the future.” Its tri-taper stem design and 3D, data-driven personalized hip planning software may offer surgeons new options. For example, they could choose the best-fit implant construct for the patients’ needs pre-operatively.
As a result, Actera could lead to a more efficient and streamlined operating room experience, according to Conformis. The company also expects a less invasive procedure and a more stable fit for initial and long-term fixation.
The company received FDA 510(k) clearance for Actera in September.
“As with our Identity and Imprint knee replacement systems, Actera is a data-driven design derived from both Conformis’ industry-leading database of thousands of patients’ anatomies and our advanced surgical planning experience,” said James Paiva, Conformis VP of marketing. “This enables Conformis to continue to design and deliver the industry’s most comprehensive portfolio of personalized products and surgical planning for total joint replacement.”